Response and survival outcomes with hypomethylating agents in an argentinean cohort of 113 patients with chronic myelomonocitic leukemia

GONZALEZ, JACQUELINE; PERUSINI, AGUSTINA; RUSSO, MARIA FLORENCIA; FUENTES, MARIA LUCIA; DELUCA, TEOFILO; BASQUIERA, ANA L; NAVICKAS, ALICIA; KORNBLIHTT, LAURA; PINTOS, NOEMÍ; NUCIFORA, ELSA; IASTREBNER, MARCELO; ENRICO, ALICIA; ARBELBIDE, JORGE; BELLI, CAROLINA B

Viena

Congreso; 27th Congress of the European Hematology Association; 2022

European Haematology Association

Background: Hypomethylating agents (HMA) are the first line option for high-risk patient and lower-risk patient with transfusion dependence, or according to worsening clinical features. Data regarding HMA efficacy in CMML has been largely retrospective, or from MDS studies that included CMML patients, with overall response rates (ORR) ranging from 40% to 50% and true CR rates being 60 years old, 18.8% a Charlson’s Index (CCI)>2, 81 (72%) were males, and 59 (52%) CMML-0, 25 (22%) CMML-1 and 29 (26%) CMML-2. At treatment initiation, 70.5% showed hemoglobin